Natera
New Study Results Boost Evidence for Natera's MRD Assays to Guide Adjuvant Therapy Decisions
Premium
The data, from a large prospective cohort, support the value of chemotherapy for ctDNA-positive patients, regardless of clinical stage.
Natera Eyes Regulatory Path for Signatera as Companion Diagnostic
The firm isn't planning a strategy for a kitted version of the test, though company officials said they were open to that in the future.
Natera Files Second Patent Infringement Suit Against NeoGenomics Subsidiary Inivata
The suit was filed the same day Natera received a new patent covering its patient-specific residual cancer testing and monitoring methods.
In Brief This Week: PerkinElmer, Hologic, Quest Diagnostics, Natera, More
News items for the week of Nov. 14, 2022.
Natera Launches Follow-On Stock Offering at $35 Per Share
Natera is offering 11,430,000 common shares at $35 per share, with additional shares available as an option to underwriters.
Nov 9, 2022
Oct 20, 2022
Apr 20, 2022
Apr 1, 2022
360Dx Top 30 Falls Slightly in March
Feb 24, 2022